News & Events
News & Events
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
September 8, 2022
C-Path’s Kristen Swingle Named PresidentSwingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
August 5, 2022
PRO Consortium Announces Publication of Open Access ArticleC-Path’s PRO Consortium announces that “Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures” was published by Quality of Life Research on July 19, 2022. The article presents the data collected by three PRO Consortium working groups to identify...
July 25, 2022
Diary for Irritable Bowel Syndrome Symptoms-Constipation Now Available for LicensingC-Path’s PRO Consortium is pleased to announce that the Diary for Irritable Bowel Syndrome Symptoms–Constipation (DIBSS–C) is available for licensing via FACIT.org. Information on the DIBSS–C and all of the PRO Consortium’s qualified measures, including item content and available translations, can be found online. Access here: https://www.c-pathcoas.org/
June 8, 2022
PRO Consortium Announces Publication of Open Access ArticleC-Path’s PRO Consortium is pleased to announce that “Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study” was published online by JTO Clinical and Research Reports on February 16, 2022. The article reports findings from analyses that used clinical trial data to evaluate the NSCLC-SAQ’s longitudinal measurement properties...